Cookson Peirce & Co. Inc. Buys Shares of 60,000 Candel Therapeutics, Inc. $CADL

Cookson Peirce & Co. Inc. purchased a new position in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 60,000 shares of the company’s stock, valued at approximately $618,000. Cookson Peirce & Co. Inc. owned approximately 0.08% of Candel Therapeutics as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of the business. Janus Henderson Group PLC bought a new position in Candel Therapeutics in the first quarter valued at about $845,000. Halter Ferguson Financial Inc. boosted its stake in shares of Candel Therapeutics by 20.9% in the 1st quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock valued at $4,430,000 after purchasing an additional 155,996 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Candel Therapeutics during the 2nd quarter valued at approximately $51,181,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Candel Therapeutics during the 2nd quarter valued at approximately $301,000. Finally, Renaissance Technologies LLC bought a new position in Candel Therapeutics in the 1st quarter valued at approximately $63,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Stifel Nicolaus initiated coverage on shares of Candel Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $22.00 target price on the stock. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Bank of America raised their price objective on Candel Therapeutics from $9.00 to $12.00 and gave the company a “neutral” rating in a report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Friday, July 17th. Finally, UBS Group restated a “buy” rating on shares of Candel Therapeutics in a report on Monday, August 17th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Candel Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $19.29.

Insider Transactions at Candel Therapeutics

In other Candel Therapeutics news, insider Francesca Barone sold 23,447 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $10.06, for a total transaction of $235,876.82. Following the completion of the sale, the insider directly owned 77,362 shares in the company, valued at approximately $778,261.72. This trade represents a 23.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the sale, the chief technology officer owned 76,865 shares of the company’s stock, valued at approximately $922,380. The trade was a 8.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 37,447 shares of company stock valued at $390,017. Company insiders own 14.30% of the company’s stock.

Candel Therapeutics Price Performance

Candel Therapeutics stock opened at $13.07 on Monday. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -9.27 and a beta of -0.51. Candel Therapeutics, Inc. has a 52-week low of $4.35 and a 52-week high of $14.00. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09. The firm has a 50 day moving average price of $10.61 and a two-hundred day moving average price of $7.91.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). Equities analysts predict that Candel Therapeutics, Inc. will post -1.29 EPS for the current year.

Candel Therapeutics Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.